The research mentioned above is based on the construction of the CCA PDX model, which provides a strong basis for the study of FGFR inhibitors as individualized treatment options for CCA patients carrying the FGFR2 fusion gene, and promotes the process of individualized treatment. Here, FGFR2 is linked to cholangiocarcinoma.